



SAMBA

Santé Mondiale du Bébé à l'Adolescent

Solutions for Advancing Maternal, Baby and Adolescent global health

Publications 2021

1. Barker ME, Hardy-Johnson P, Weller S, Haileamalak A, Jarju L, **Jesson J**, Krishnaveni GV, Kumaran K, **Leroy V**, Moore SE, Norris SA, Patil S, Sahariah SA, Ward K, Yajnik CS, Fall C, collaboration T. How do we improve adolescent diet and physical activity in India and sub-Saharan Africa? Findings from the Transforming Adolescent Lives through Nutrition (TALENT) consortium. *Public Health Nutr.* 2021.24(16):5309-17. [doi: 10.1017/S1368980020002244](#).
2. **Dassi Tchoupa Revegue MH**, Takassi UE, Tanoh Eboua F, **Desmonde S**, Amoussou-Bouah UB, Bakai TA, **Jesson J**, **Dahourou DL**, Malateste K, Aka-Dago-Akribi H, **Raynaud JP**, Arrivé E, **Leroy V**. 24-Month Clinical, Immuno-Virological Outcomes, and HIV Status Disclosure in Adolescents Living With Perinatally-Acquired HIV in the leDEA-COHADO Cohort in Togo and Côte d'Ivoire, 2015-2017. *Front Pediatr.* 2021.9:582883. [doi: 10.3389/fped.2021.582883](#).
3. **Desmonde S**, Ciaranello AL, Malateste K, Musick B, Patten G, Vu AT, Edmonds A, Neilan AM, Duda SN, Wools-Kaloustian K, Davies MA, **Leroy V**; leDEA Consortium. Age-specific mortality rate ratios in adolescents and youth aged 10-24 years living with perinatally versus nonperinatally acquired HIV. *AIDS.* 2021.35(4):625-632. [doi: 10.1097/QAD.0000000000002765](#).
4. Han WM, Law MG, Egger M, Wools-Kaloustian K, Moore R, McGowan C, Kumarasamy N, **Desmonde S**, Edmonds A, Davies MA, Yiannoutsos C, Althoff KN, Cortes CP, Mohamed TJ, Jaquet A, Anastos K, Euvrard J, Castelnuovo B, Salters K, Coelho LE, Ekouevi DK, Eley B, Diero L, Zaniewski E, Ford N, Sohn AH, Kariminia A; leDEA collaboration. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. *Lancet HIV.* 2021.8(12):e766-e775. [doi: 10.1016/S2352-3018\(21\)00265-4](#).
5. Lyun V, Technau KG, Vinikoor M, Yotebieng M, Vreeman R, Abuogi L, **Desmonde S**, Edmonds A, Amorissani-Folquet M, Davies MA; leDEA Collaboration. Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006-17): a retrospective cohort study. *Lancet HIV.* 2021.8(6):e353-e362. [doi: 10.1016/S2352-3018\(21\)00004-7](#).
6. **Jesson J**, Ephoevi-Ga A, Aké-Assi MH, Koumakpai S, N'Gbeche S, Dainguy E, Malateste K, Carrié H, D'Almeida M, Eboua FT, Takassi E, Amorissani-Folquet M, **Leroy V**; leDEA West African Pediatric Collaboration (**Dahourou D**, **Desmonde S** collaborators). Assessment of dietary diversity and nutritional support for children living with HIV in the leDEA pediatric West African cohort: a non-comparative, feasibility study. *BMC Nutr.* 2021. 7(1):83. [doi: 10.1186/s40795-021-00486-4](#).
7. **Jesson J**, Kouakou EK, Hardy-Johnson P, Ngoran-Theckly P, Kehoe SH, Adonis L, Fall C, **Leroy V**, Barker M, Weller S; TALENT Collaboration. Adolescent nutrition and physical activity in low-income suburbs of Abidjan, Côte d'Ivoire: the gap between knowledge, aspirations and possibilities. *Public Health Nutr.* 2021.24(16):5227-5237. [doi: 10.1017/S1368980020001809](#).

8. **Jesson J**, Kouakou EK, Kumaran K, Adonis L, Wrottesley SV, **Leroy V**, Fall C, collaboration T. A scoping review of literature describing the nutritional status and diets of adolescents in Cote d'Ivoire. *Public Health Nutr.* 2021.24(16):5261-76. [doi: 10.1017/S1368980020002621](https://doi.org/10.1017/S1368980020002621).
9. Kassanjee R, Johnson LF, Zaniewski E, Ballif M, Christ B, Yiannoutsos CT, Nyakato P, **Desmonde S**, Edmonds A, Sudjaritruk T, Pinto J, Vreeman R, **Dahourou DL**, Twizere C, Kariminia A, Carlucci JG, Kasozi C, Davies MA; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Global HIV mortality trends among children on antiretroviral treatment corrected for under-reported deaths: an updated analysis of the International epidemiology Databases to Evaluate AIDS collaboration. *J Int AIDS Soc.* 2021. 24 Suppl 5(Suppl 5):e25780. [doi: 10.1002/jia2.25780](https://doi.org/10.1002/jia2.25780).
10. Lortie E, Letouzey M, Torchin H, Foix L'Helias L, Gras-Le Guen C, Benhammou V, Boileau P, Charlier C, Kayem G; EPIPAGE-2 Obstetric Writing Group (**Arnaud C, Gascoin G, Sizun J, Duffaut C, Vayssi re C, Alberge C** collaborators). Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. *BJOG.* 2021. [doi: 10.1111/1471-0528.17081](https://doi.org/10.1111/1471-0528.17081). Online ahead of print.
11. Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Sa di Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team (**Leroy V** collaboratrice). ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. *BMC Infect Dis.* 2021.21(1):5. [doi: 10.1186/s12879-020-05672-6](https://doi.org/10.1186/s12879-020-05672-6).
12. Pressiat C, Toni TD, Treluyer JM, Yonaba C, **Dahourou DL**, Malateste K, Seguin-Devaux C, **Leroy V**, Hirt D; MONOD ANRS Study Group. High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy. *AIDS.* 2021.35(14):2409-2410. [doi: 10.1097/QAD.0000000000003043](https://doi.org/10.1097/QAD.0000000000003043).
13. Pressiat C, Dainguy E, Treluyer J, Yonaba C, Urien S, Eboua F, Foissac F, **Dahourou DL**, Bouazza N, Malateste K, **Desmonde S**, Pruvost A, **Leroy V**, Hirt D, for the MONOD ANRS Study Group. Comparison of three galenic forms of lamivudine in young West African children living with HIV. *Antiviral Therapy.* 2021.26(6-8):135965352110582. [doi: 10.1177/13596535211058267](https://doi.org/10.1177/13596535211058267)
14. Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpanmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Sa di Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team (**Leroy V** collaboratrice). Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. *N Engl J Med.* 2021. (27):2531-2543. [doi: 10.1056/NEJMoa2108793](https://doi.org/10.1056/NEJMoa2108793).